Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Butler University, Indianapolis, Indiana, USA.
Clin Ther. 2012 Jun;34(6):1459-65. doi: 10.1016/j.clinthera.2012.05.005. Epub 2012 May 31.
Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited.
The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital.
This was a prospective observational study of patients aged >30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen.
A total of 332 patients, with a median age of 5 years (interquartile range, 1.9-12 years) and median weight of 19.9 kg (interquartile range, 11.7 - 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references.
Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.
已描述成人患者使用哌拉西林/他唑巴坦(PT)延长输注,但儿童患者的数据有限。
本研究的目的是确定在儿童医院使用延长输注 PT 给药方案作为标准治疗的可行性。
这是一项对入住独立的三级儿童保健医院后接受 PT 治疗的>30 天患者的前瞻性观察性研究。在将延长输注 PT 给药方案作为标准给药方案实施后,前瞻性评估接受 PT 治疗的患者的给药方案改变的存在和原因。
共有 332 例中位年龄为 5 岁(四分位距,1.9-12 岁)、中位体重 19.9kg(四分位距,11.7-37.6kg)的患者接受了 PT(基于哌拉西林成分的 100mg/kg)。92%(n=304)的患者在 PT 治疗期间使用了延长输注 PT。28 例(8%)患者接受了 30 分钟的传统输注,其中 19 例由延长输注改为传统输注,28 例中 9 例为经验性给予传统输注 PT。最常见的不使用延长输注的原因是同时使用万古霉素(17/28[61%])和缺乏与 PT 的相容性数据。报告的剂量错误很少(1.8%[n=6])。观察到的剂量错误可能归因于我院的整体医嘱流程,该流程要求医嘱的剂量为每千克毫克数,而不是儿科剂量参考中常见的基于哌拉西林成分的剂量。
本研究结果表明,延长输注 PT 给药方案在本特定儿童医院是可行的。92%的患者接受了我院首选的给药方案;少数患者仍需要接受传统的输注时间。